Home healthcare provider Addus HomeCare (NASDAQ: ADUS) met Wall Street’s revenue expectations in Q3 2026, with sales up 7% year on year to $387.7 million. Its non-GAAP profit of $1.83 per share was 2.1% above analysts’ consensus estimates.

Is now the time to buy ADUS? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Addus HomeCare delivered results in line with Wall Street’s expectations for the third quarter, with modest revenue growth and a slight non-GAAP profit outperformance. Management attributed the quarter’s performance to steady organic growth in personal care, ongoing hiring momentum, and operational improvements in hospice and home health. CEO Dirk Allison cited the integration of recent acquisitions and the rollout of Addus’s caregiver app as contributors to service improvements and operational efficiency, particularly in key markets like Texas and Illinois.

Looking forward, management’s outlook is shaped by several factors, including the closing of the AccentCare personal care acquisition and continued focus on geographic density. CFO Brian Poff emphasized that the company will pursue additional clinical acquisitions as market conditions allow, while monitoring potential Medicaid rate changes in key states. Management also highlighted ongoing technology investments and the implementation of the Homecare Homebase platform to drive further operational gains, stating, “We expect to realize additional efficiencies across our major markets as we complete this transition.”

Key insights from management’s remarks

Management pointed to ongoing cost discipline, targeted acquisitions, and operational investments as the main drivers behind the quarter’s results and future strategy.

• Personal care segment stability: The personal care services segment saw steady organic revenue growth, supported by increased hiring and improved service fill rates enabled by the internally developed caregiver app.
• AccentCare acquisition progress: Addus advanced toward closing the AccentCare personal care acquisition, positioning the company to expand market share and private pay exposure. The deal is expected to add $280 million in annualized revenue and increase operational density in major states.
• Hospice and home health trends: Hospice reported consistent volume and reimbursement growth, while home health returned to positive year-over-year revenue growth after operational and leadership changes. This segment also benefited from the Clinical Bridge Program, which channels referrals across care levels in overlapping markets.
• State and federal rate updates: Management highlighted a recent rate increase in New Mexico and anticipated further rate support from other states. Federal hospice reimbursement updates were described as favorable, with expectations for a positive adjustment in home health rates.
• Cost structure and margin improvement: General and administrative expenses declined as a percentage of revenue, reflecting leverage from top-line growth and ongoing efficiency initiatives. Management expects further margin benefits as the AccentCare integration progresses and technology adoption increases.

Drivers of future performance

Addus HomeCare’s outlook centers on successful acquisition integration, ongoing rate environment developments, and further operational and technology enhancements.

• AccentCare integration and synergy: Management aims to quickly integrate AccentCare’s personal care business, targeting improved margins through G&A savings and leveraging best practices to raise private pay exposure. The acquisition is expected to increase annual revenue by about 19%.
• Medicaid and reimbursement environment: Future performance will depend on state-level decisions regarding Medicaid rate increases, particularly in Illinois and Texas. Management expects modest organic growth unless additional rate support materializes, with the opportunity to accelerate if favorable budget outcomes occur.
• Clinical acquisition strategy: The company plans to be more aggressive in pursuing clinical acquisitions in home health and hospice, as management believes market conditions and asset pricing are becoming more favorable. Success in these initiatives could alter the business mix and impact margins.

Catalysts in upcoming quarters

In the coming quarters, our analysts will focus on (1) the pace and effectiveness of AccentCare integration, including realization of G&A and margin synergies; (2) state-level developments on Medicaid rate increases in key markets such as Texas and Illinois; and (3) the impact of technology rollouts, particularly the Homecare Homebase platform, on operational efficiency. Progress in clinical acquisition activity and evolving reimbursement policies will also be key markers of execution.

Addus HomeCare currently trades at $125.87, in line with $126.55 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.